Abstract 8504: E4697: Phase III Cooperative Group Study of Yeast Derived GM-CSF vs Placebo as Adjuvant Treatment of Patients with Completely Resected Stage.

Slides:



Advertisements
Similar presentations
FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev
Advertisements

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.
Adjuvant Therapy for Melanoma What is the role of PegIFN in relation to HDIFN? John M. Kirkwood, MD Professor of Medicine, Dermatology and Translational.
Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.
Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.
A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Inhibitor Gefitinb in Completely Resected Stage.
Robertson JFR et al. J Clin Oncol 2009;27(27):
Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.
Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.
1Stopeck A et al. Proc SABCS 2010;Abstract P
Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in.
Intergroup trial CALGB 80101
NCCTG N9831 May 2005 Update Perez EA, Suman VJ, Davidson N, Martino S, Kaufman P, on Behalf of NCCTG, ECOG, SWOG, CALGB.
CI - 1 Cure Rate Models and Adjuvant Trial Design for ECOG Melanoma Studies in the Past, Present, and Future Joseph Ibrahim, PhD Harvard School of Public.
The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.
Adjuvant Therapy of Colon Cancer 2005 Daniel G. Haller, M.D. Abramson Cancer Center at the University of Pennsylvania Philadelphia PA.
Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.
The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.
Impact of age and comorbidities on treatment effect, tolerance and toxicity in metastatic colorectal cancer (mCRC) patients (pts) treated on CALGB
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
Outcomes Following Adjuvant 5-FU based Treatment (AT) for Colon Cancer vs Impact on Recurrence Rate, Time from Recurrence to Death.
T Andre, E Quinaux, C Louvet, E Gamelin, O Bouche, E Achille, P Piedbois, N Tubiana-Mathieu, M Buyse and A de Gramont. Updated results at 6 year of the.
Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized.
Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin plus Cytarabine versus Placebo plus.
Extended adjuvant treatment with anastrozole: results from the ABCSG Trial 6a R Jakesz, H Samonigg, R Greil, M Gnant, M Schmid, W Kwasny, E Kubista, B.
AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.
FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,
Kang Y et al. Proc ASCO 2010;Abstract LBA4007.
Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of the stomach and lower.
Baselga J et al. Proc SABCS 2010;Abstract S3-3.
The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB Nadine A. Jackson, Charles S.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
CB-1 Background of Pancreatic Cancer & NCIC CTG PA.3 Study Design Malcolm Moore, MD Professor of Medicine and Pharmacology Princess Margaret Hospital Chair,
San Antonio Breast Cancer Symposium, December 8-12, 2015
Age > 50 Abstract Background Limited data exists regarding outcomes and AT benefit/toxicity in Y pts with stage II and III CC. We examined overall survival.
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
Results from a Randomized Phase III Trial of Decitabine versus Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed.
INTERGROUP STUDY 0148 BMS CA Effect of TAXOL® (paclitaxel) and Doxorubicin Dose on Disease Free and Overall Survival of Patients with Node Positive.
A Phase III, Open-Label, Randomized, Multicenter Study of Eribulin Mesylate versus Capecitabine in Patients with Locally Advanced or Metastatic Breast.
Endpoints in adjuvant trials: a systematic review of the literature in colon cancer and proposed definitions for future trials Marc E. Buyse.
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.
Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.
PHARE Trial Results of Subset Analysis Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer Pivot X et al. Proc SABCS 2012;Abstract.
J Clin Oncol 30: R2 윤경한 / Prof. 김시영 Huan Jin, Dongsheng Tu, Naiqing Zhao, Lois E. Shepherd, and Paul E. Goss.
ADJUVANT CAPECITABINE AND OXALIPLATIN FOR GASTRIC CANCER AFTER D2 GASTRECTOMY (CLASSIC): A PHASE 3 OPEN-LABEL,RANDOMISED CONTROLLED TRIAL Yung-Jue Bang*,
Presented By Shin Fujita at 2016 ASCO Annual Meeting
Phase III Clinical Trial of FOLFOX with or without Cetuximab in Resected Stage 3 Colon Cancer: Cooperative Group Trial N0147 (NCCTG*,
A cura di Filippo de Marinis
CCO Independent Conference Highlights
CCO Independent Conference Highlights
Alessandra Gennari, MD PhD
Palumbo A et al. Proc ASH 2012;Abstract 200.
Attal M et al. Proc ASH 2010;Abstract 310.
S1207: Phase III randomized, placebo-controlled trial adding 1 year of everolimus to adjuvant endocrine therapy for patients with high-risk, HR+, HER2-
Joensuu H et al. Proc ASCO 2011;Abstract LBA1.
Barrios C et al. SABCS 2009;Abstract 46.
Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011
LBA-4 A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy.
Adjuvant Therapy in Melanoma
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
RTOG 9704: A Phase III Study of Adjuvant Pre and Post Chemoradiation 5-FU vs. Gemcitabine for Resected Pancreatic Adenocarcinoma A U.S. GI INTERGROUP.
Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) +/- cetuximab for patients with untreated metastatic adenocarcinoma of the.
Aimery de Gramont Association between 3 year Disease Free Survival and Overall Survival delayed with improved survival after recurrence in patients receiving.
Presentation transcript:

Abstract 8504: E4697: Phase III Cooperative Group Study of Yeast Derived GM-CSF vs Placebo as Adjuvant Treatment of Patients with Completely Resected Stage III-IV Melanoma DH Lawson, SJ Lee, AA Tarhini, KA Margolin, MS Ernstoff, JM Kirkwood Winship Cancer Institute of Emory University, Dana-Farber Cancer Institute, University of Pittsburgh Cancer Institute, University of Washington, Dartmouth Hitchcock Medical Center

Objectives Primary objective: –To compare OS of patients given GM-CSF vs placebo Secondary objectives –To compare DFS of patients with GM-CSF vs placebo –To compare DFS of HLA-A2+ patients given peptide vaccine vs. placebo –To compare OS of HLA-A2+ patients given peptide vaccine vs. placebo

GM-CSF+ Peptide Vaccine Placebo+ Peptide Vaccine GM-CSF+ Peptide Placebo Placebo+ Peptide Placebo RANDOMIZE GM-CSF GM-CSF Placebo RANDOMIZE HLA-A2 Positive HLA-A2 Negative Stratify: HLA-A2 Status 1. Positive 2. Negative Site of Metastases 1. Visceral 2. Non-visceral 3. Visceral/Non-visceral Number of Metastases or more

Eligibility for E4697: Stage III Intransit metastases including local recurrence Gross extracapsular extension Recurrence in previously resected nodal basin Four or more involved nodes Ulcerated primary with any clinically involved nodes Locoregional recurrence after IFN or S0008

Eligibility for E4697 Resected locoregional mucosal melanoma Completely resected stage IV melanoma, –Cutaneous, mucosal, ocular, and unknown 1º

Treatment Plan GM-CSF 250 mcg SC 14 days of 28 for one year (13 cycles) Patients with resectable recurrences encouraged to continue 6 months past recurrence or for one year, whichever is longer Disease assessments every 3 mos

Treatment Plan Vaccinations on days 1 and 15 of first cycle, then day 1 of subsequent cycles. Peptides used: –Tyrosinase: (370D) –gp-100: (210M) –MART-1: 27-35

Statistical Considerations 800 patients gives 80% power to detect a 33% increase in median survival from 40 to 53 months with 2-sided type 1 error rate of % power to detect 24% increase in DFS from 11 to 13.6 months Placebo controlled to enhance validity of the DFS endpoint

E4697: Accrual 815 pts accrued between December 29, 1999 and October 31, 2006 –53.5% HLA-A2+ –46.5% HLA-A2- 72 ineligible 743 included in this analysis –368 received GMCSF –375 received GMCSF-placebo

Data Analyses Unblinding specified in protocol at 30 months from completion of treatment of the last patient (April, 2009) even if full information not reached by then.

Data Analyses September 2009 analysis Positive effect of GM-CSF on DFS (p=.03) with Hazard Ratio (HR) 0.82, 95% CI(.69,.98) No significant effect on OS (p=.55) with HR 0.94, 95% CI (.75, 1.16)

Data Analyses Updated analysis for ASCO planned for April 2010

Current Status 345 deaths 86% information time Full information anticipated in 2014 Results of April, 2010 analysis presented today

DFS by GM-CSF (n=743) P = 0.14 HR = 0.88, 95% CI(.73,1.04) Median DFS Placebo: 9.2 mos, 95% CI (7.68, 12.48) GM-CSF:11.5 mos, 95% CI (9.72, 15.48)

OS by GM-CSF Treatment Status P= 0.78 HR= 0.96, 95% CI(.78,1.04) Median OS: Placebo : 62.4 mos, 95% CI (45.6, -) GM-CSF: 69.6 mos, 95% CI (50.4, -)

Effect of Peptide Vaccination on Disease Free and Overall Survival in HLA-A2+ Patients

DFS by PEP in HLA-A2+ (n=398) P=.709 HR=.93, 95%CI(.73,1.27)

OS by PEP in HLA-A2+ (n=398) P =.670 HR=.94, 95%CI(.70,1.26)

Subset Analysis of Effect of GMCSF on OS and DFS by Stage Stage IIIB and IIIC: 374 pts Stage IV: 258 pts

Stage III Melanoma p = 0.52 HR=.92, 95%CI(.72,1.17) DFSOS p = 0.80 HR=.97, 95%CI(.71,1.31)

Stage IV Melanoma DFS OS P= 0.04 HR=.74, 95%CI(.56,.99) P= 0.07 HR=.72, 95%CI(.50,1.02)

Conclusions Neither GMCSF nor peptide vaccination achieved OS and DFS objectives There is a suggestion of favorable effect of GMCSF on DFS Subset analysis suggests effects of GMCSF on DFS and OS are largest among Stage IV subjects

Conclusions Further study of adjuvant GMCSF is warranted (patients, dose, duration) Use of GMCSF in the adjuvant setting is worthy of discussion (IFN failures, resected stage IV) Laboratory immunologic responses in relation to clinical outcome are under investigation

Acknowledgements Coordinating Centers of ECOG, SWOG, and CALGB PI’s, Research Nurses and Coordinators at the sites Carol Hill, RN, PIN nurse As always, our patients and their families